CX-8998 Exhibits Promise in Essential Tremor Despite Failing to Meet Primary End Point
May 8th 2019Although the primary end point of centrally video-rated TETRAS Performance Subscale did not achieve statistical significance, CX-8998-treated patients showed significant improvements in a number of other measurements.
Amit Rakhit, MD, MBA: Developing Therapies for Fragile X Syndrome
May 8th 2019The chief medical officer and head of Research & Development at Ovid Therapeutics spoke about the Visual Analog Scale that the company developed to help better understand the impact that potential treatments have on patients with Fragile X syndrome.
Orally Dissolving Rimegepant Rapidly Lowers Pain, Improves Symptoms for Acute Migraine
May 7th 2019A 75 mg orally dissolving tablet formulation of the calcitonin gene-related peptide receptor antagonist met both co-primary end points of freedom from the patient-indicated most bothersome symptom and freedom from pain at 2 hours.
Fingolimod Reduces ARR in Patients With MS Who Switch From Other DMTs
May 7th 2019The sphingosine1-phosphate receptor modulator was shown to annualize relapse rates by more than 70% for patients switching from other disease-modifying therapies such as dimethyl fumarate; teriflunomide, and daclizumab.
CBD Has Potential for a Variety of Epilepsy Conditions, Expert Says
May 7th 2019The medical director of neurology and co-director of the Jane and John Justin Neurosciences Center at Cook Children’s Hospital spoke about what CBD has shown in clinical trials and how it could make an impact outside of Lennox-Gastaut and Dravet syndromes.
Eculizumab Significantly Reduces Relapse Risk in Neuromyelitis Optica Spectrum Disorder
May 7th 2019The treatment was efficacious in patients with AQP4-IgG-positive NMOSD, which accounts for nearly three-quarters of the population with the disorder, for which there is currently no approved treatment.
Jacqueline French, MD: Inhaled Alprazolam for Aborting Predictable Seizure Episodes in Epilepsy
May 6th 2019The professor of neurology and director of translational research and epilepsy clinical trials at NYU Langone spoke about the results of a phase 2b open-label feasibility study of this novel delivery method for abortive seizure treatment in patients with epilepsy.
Isradipine Fails to Slow Early Parkinson Disease Progression in Phase 3 Study
May 5th 2019Although animal models and early phase studies suggested some potential for the hypertension medication to slow disability progression in Parkinson disease, a phase 3 assessment showed a lack of treatment effect.
CBD Reduces Convulsive, Total Seizure Frequency In Dravet Syndrome
May 3rd 2019In patients with Dravet syndrome who had discontinued an average of 4 antiepileptics drugs, while taking a mean of 3, cannabidiol reduced the incidence of seizures almost in half in doses of both 10 mg/kg and 20 mg/kg per day.
Diagnostic Guidelines Developed for LATE, New Alzheimer-Like Brain Disorder
May 2nd 2019The report includes consensus-based recommendations, which consist of guidelines for the diagnosis and staging of LATE-neuropathological change—defined by stereotypical TDP-43 proteinopathy both with or without simultaneous hippocampal sclerosis pathology, in older adults.
FDA Clears Advanced Brain Visualization Software for Deep Brain Stimulation Surgery
May 2nd 2019The proprietary software utilizes sophisticated algorithms and 7T MRI data to predict the location of the subthalamic nuclei, a key target for deep brain stimulation for the treatment of Parkinson disease.
Sleep Apneas Show Association With Tau Accumulation in Cognitively Unimpaired
May 1st 2019Researchers found that cognitively unimpaired patients with apneas had an average of 4.5% higher levels of tau in the entorhinal cortex than those who did not have apneas, after controlling for several other factors.